ARTV Stock — Artiva Biotherapeutics Inc.: Cash, EV, Pipeline

What they do

We are a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers.

Source: 10-K FY2025 via SEC EDGAR

Share price

$4.09

Market cap

$199.9M

Cash

$319.1M

Enterprise value

-$119.2M

Balance sheet

Cash	$319.1M
Debt	$0.0M
Net cash	$319.1M
Enterprise value	-$119.2M
Basic shares	49.4M shares
Fully diluted shares	56.5M shares
Fully diluted market cap	$231.0M
Cash per share	$6.46
Quarterly burn	$20.4M
Cash runway	17.2 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-11.

Share structure

Common

48.9M

Pre-funded warrants

2.2M

Options

1.1M

RSUs

3.7M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

0.6M

FDSO

56.5M

Cap table as of 2026-06-30.

Price history

Loading ARTV daily closes…

Loading price history…

Next catalyst

AB-101 · Sep 12 - Oct 24 in 10 mo · Phase 1 · Lupus Nephritis - WHO Class III; Lupus Nephritis - WHO Class IV; Refractory Systemic Lupus Erythematosus

Recently reported

AlloNK (AB-101) Phase 2 Negative · 2026-10-27

Phase 2a basket trial · B-cell-driven autoimmune diseases (rheumatoid arthritis and others)

Primary: Not applicable - program discontinuation announcement reporting updated durability of clinical response and safety from the AlloNK (AB-101) plus rituximab autoimmune program — Longer-term follow-up showed durability of clinical response did not meet the threshold the Company required to support continued development; Artiva discontinued AlloNK development, will dose no additional patients, and will not initiate the planned Phase 3 pivotal trial

· Deep B-cell depletion and clinical activity remained consistent with previously reported findings; durability on longer-term follow-up was the failing element

· FDA asked Artiva to pause enrollment and dosing in the Phase 2a study after the Grade 5 leukoencephalopathy report; planned Phase 3 enrollment and dosing were also paused

· Workforce reduction of approximately 94%

· Cash, cash equivalents and investments of approximately $319.1 million as of September 30, 2026 (preliminary and unaudited)

· Leerink Partners engaged to evaluate strategic alternatives, which may include a merger, business combination, sale or licensing of assets, or dissolution and liquidation

Safety: Two Grade 5 events: a Phase 2a participant died from leukoencephalopathy assessed as likely related to fludarabine-associated neurotoxicity (lymphodepletion with cyclophosphamide and fludarabine); a second participant died suddenly approximately two months after initiating treatment, assessed as unrelated to any component of the study treatment, cause not determined

Source release →

AB-101 Phase 2 Negative · 2026-10-01

AB-101 · rheumatoid arthritis, pemphigus vulgaris, granulomatosis with polyangiitis

Source release →

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Sep 12 - Oct 24 in 10 mo	AB-101	Phase 1	Lupus Nephritis - WHO Class III; Lupus Nephritis - WHO Class IV; Refractory Systemic Lupus Erythematosus	—
Sep 12 - Oct 24 in 10 mo	GCC2005	Phase 1	Lymphoma, T-Cell	—
Feb 12 - Mar 25 in 15 mo	Allogeneic NK Cells	Phase 2	Refractory Rheumatoid Arthritis (RA); Idiopathic Inflammatory Myopathies (IIMs); Systemic Sclerosis (SSc)	2H 2026 Est. Nov 11, 2026 · half midpoint 2H 2026 Est. Nov 11, 2026 · half midpoint

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

AlloNK

Phase 3 · Active Modality: allogeneic NK cell therapy

Partnerships GC Cell: option/license agreements plus master manufacturing agreement for NK cell therapy platform and core products

Indications

refractory rheumatoid arthritis (with rituximab) (Phase 3)
Sjögren's disease (with rituximab) (Phase 1)
systemic sclerosis (with rituximab) (Phase 1)

Catalysts

— first half of 2026

Status note Off-the-shelf allogeneic NK cell therapy given with rituximab. FDA aligned on a single registrational randomized controlled Phase 3 trial in refractory RA (two doses with rituximab following low-dose conditioning). Phase 1/2 B-NHL trial completed July 2025; long-term follow-up discontinued to focus resources on autoimmune indications.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Allogeneic NK Cells
Lead indication	Refractory Rheumatoid Arthritis (RA)
Lead phase	Phase 2
Active trials	2
Collaborator trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06991114	Phase 2	Recruiting	Sponsor	ARTV	—	Refractory Rheumatoid Arthritis (RA); Idiopathic Inflammatory Myopathies (IIMs); Systemic Sclerosis (SSc)	2H 2026 Est. Nov 11, 2026 · half midpoint 2H 2026 Est. Nov 11, 2026 · half midpoint
NCT06265220	Phase 1	Active, not recruiting	Sponsor	ARTV	—	Lupus Nephritis - WHO Class III; Lupus Nephritis - WHO Class IV; Refractory Systemic Lupus Erythematosus	—
NCT06581562	Phase 1	Recruiting	Collaborator	IRIS Research and Development, LLC	—	Rheumatoid Arthritis; Pemphigus Vulgaris; Granulomatosis With Polyangiitis	—
NCT06699771	Phase 1	Recruiting	Collaborator	GC Cell Corporation	—	Lymphoma, T-Cell	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 2 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 4 active trials for Artiva Biotherapeutics, Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
RA Capital Management	17,955,642	+8,102,340	1.51%	2026-08-14
ADAR1 Capital Management	118,624	+118,624	0.05%	2026-08-14
DAFNA Capital	67,101	+67,101	0.12%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

ARTV — Artiva Biotherapeutics Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Recently reported

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

ARTV — Artiva Biotherapeutics Inc.